Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASFRA:PI3 -4.21%68 Cash-to-Debt is 4.83 as of Jun. 2026, which is at its 10-year median of 4.83. GuruFocus rates FRA:PI3 with a GF Score™ of 68/100 and a GF Value™ of €27.06 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,397 Biotechnology companies, Gubra AS ranks worse than 54.33% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Gubra AS's cash to debt ratio for the quarter that ended in Jun. 2026 was 4.83.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Gubra AScould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Gubra AS's Cash-to-Debt or its related term are showing as below:
FRA:PI3'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.71 Med: 4.83 Max: 29.37
Current: 4.83
During the past 7 years, Gubra AS's highest Cash to Debt Ratio was 29.37. The lowest was 0.71. And the median was 4.83.
FRA:PI3's Cash-to-Debt is ranked worse than 54.33% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs FRA:PI3: 4.83
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Gubra AS Cash-to-Debt Related Terms
Gubra AS Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Gubra AS's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:PI3 vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Gubra AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Gubra AS's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (FRA:PI3) has a Cash-to-Debt of 4.83 as of Jun. 2026. This is near median its historical median of 4.83. Over the past decade, Gubra AS's Cash-to-Debt has ranged from 0.71 to 29.37. According to the industry distribution chart, Gubra AS ranks #759 out of 1397 companies in the Biotechnology industry, placing it in the top 54.3%.
Is Gubra AS's Cash-to-Debt too high?
Gubra AS's current Cash-to-Debt of 4.83 is near median its 10-year median of 4.83. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 29.37. The Biotechnology industry median Cash-to-Debt is 6.72. Gubra AS's value of 4.83 is 28.1% below this industry median. Based on the distribution chart, Gubra AS ranks #759 out of 1397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gubra AS has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #759 out of 1397 companies for Cash-to-Debt. This places Gubra AS in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Gubra AS's value of 4.83 is 28.1% below this benchmark. Historically, Gubra AS's own Cash-to-Debt has ranged from 0.71 to 29.37 over the past decade. While the company's 10-year median is 4.83 vs. the industry median of 6.72, Gubra AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current Cash-to-Debt of 4.83 is 28.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Cash-to-Debt is 4.83, which is near median its own 10-year median of 4.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Significantly Overvalued. The stock's GF Value™ is €27.06, compared to a current price of €45.50 — trading 68.1% above its estimated fair value. The current Cash-to-Debt is 4.83, which is near median its 10-year median of 4.83 and 28.1% below the Biotechnology industry median of 6.72. Gubra AS's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current Cash-to-Debt is 4.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued.
The current stock price of €45.50 is trading 68.1% above its estimated GF Value™ of €27.06.
GuruFocus considers Gubra AS to be Significantly Overvalued.
Key valuation signals for FRA:PI3:
Cash-to-Debt: 4.83 (near median its 10-year median of 4.83)
GF Value™: €27.06 vs. price of €45.50 (68.1% above fair value)
Industry Position: 28.1% below the Biotechnology median (#759 of 1397)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
68GF Score
Get the complete analysis for FRA:PI3
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
